Tanaka Y, Hirata S, Kubo S, et al. Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Ann Rheum Dis 2015;74:389–95. In table 3 (B) values of 95% CI were not correct. The corrected table 3 (B) is given below.
Table 3.
(B) Multivariate logistic regression analysis
| Items | Odds | 95%CI | Chi-square | p Value |
|---|---|---|---|---|
| Age (years) | 0.963 | 0.906 to 1.024 | 1.441 | 0.2300 |
| ADA admin periods (weeks) | 0.985 | 0.959 to 1.011 | 1.254 | 0.2629 |
| DAS28-ESR | 0.143 | 0.029 to 0.711 | 5.653 | 0.0174* |
| RF (U/mL) | 1.012 | 0.996 to 1.028 | 2.127 | 0.1448 |
Univariate logistic regression analysis was performed using items with p<0.1 in table 2 to investigate factors related to sustained remission for 1 year after ADA discontinuation. Then, multivariate analyses were conducted using the variables with p<0.2 in the univariate analysis. Using the DAS28-ESR values which were significant in logistic analysis, ROC analysis was conducted with the response (dependent) variable of if DAS28-ESR <2.6 (1) or ≥2.6 (0) 1 year after discontinuation of ADA and the explanatory variable of DAS28-ESR at the timing of ADA discontinuation.
*p<0.01: Wald test.
ADA, adalimumab; DAS28, disease activity score 28; RF, rheumatoid factor.